Devonian Health Group Inc. (CVE:GSD – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$5.10 and last traded at C$5.10, with a volume of 316 shares trading hands. The stock had previously closed at C$7.17.
Devonian Health Group Stock Performance
The firm has a fifty day simple moving average of C$10.50 and a 200-day simple moving average of C$11.34. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36. The company has a market cap of C$14.18 million, a PE ratio of -2.27 and a beta of 0.44.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Further Reading
- Five stocks we like better than Devonian Health Group
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
